Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1–2 tamibarotene plus decitabine in relapsed/refractory pediatric solid tumors
jRCT2080224007Phase 2Completed
- Sponsor
- Osaka City General Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamibarotene and decitabine in Nonhematologic neoplasms, Bone and soft tissue sarcoma, blastoma and 3 more, sponsored by Osaka City General Hospital. Primary endpoints: Phase 1 safety and dose-finding endpoint and Phase 2 antitumor activity endpoint. Started Aug 2018; status: completed.
02
Drugs
tamibarotenedecitabine
03
Conditions
Nonhematologic neoplasmsBone and soft tissue sarcomablastomagerm cell tumor (GCT)central nervous system tumor
Beyond the preview
Go deeper on jRCT2080224007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224007.